Contemporary post surgical management of differentiated thyroid carcinoma

Clinical Oncology

Volumn 22, Issue 6, 2010, Pages 419-429

  Tala, H ^a   Tuttle, R M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Follow up; Risk adapted management; Thyroid cancer

Indexed keywords

RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROTROPIN;

ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CROSS-SECTIONAL STUDY; DIFFERENTIATED THYROID CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MOLECULAR BIOLOGY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; DISEASE MANAGEMENT; MORTALITY; PATHOLOGY; POSTOPERATIVE CARE; PROGNOSIS; THYROID NEOPLASMS; TUMOR RECURRENCE;

DISEASE MANAGEMENT; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE CARE; PROGNOSIS; RISK ASSESSMENT; THYROID NEOPLASMS;

EID: 77954761574     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.04.005     Document Type: Article

References (65)

1. Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
2. Tuttle R.M. Risk-adapted management of thyroid cancer. Endocr Pract 2008, 14:764-774.
3. Tuttle R.M., Leboeuf R., Martorella A.J. Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am 2007, 36:753-778.
4. Tuttle R.M., Leboeuf R., Shaha A.R. Medical management of thyroid cancer: a risk adapted approach. J Surg Oncol 2008, 97:712-716.
5. Tuttle R.M., Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am 2008, 37(2):419-435.
6. van Heerden J.A., Hay I.D., Goellner J.R., et al. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 1992, 112:1130-1136. discussion 6-8.
7. Liu J., Singh B., Tallini G., et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 2006, 107:1255-1264.
8. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006, 6:292-306.
9. Fagin J.A., Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008, 22:955-969.
10. Baloch Z.W., LiVolsi V.A. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid 2001, 11:637-645.
11. Nikiforova M.N., Nikiforov Y.E. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008, 8:83-95.
12. Ward L.S., Morari E.C., Leite J.L., et al. Identifying a risk profile for thyroid cancer. Arq Bras Endocrinol Metabol 2007, 51:713-722.
13. Kebebew E., Weng J., Bauer J., et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007, 246:466-470. discussion 70-71.
14. Lupi C., Giannini R., Ugolini C., et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92:4085-4090.
15. Robbins R.J., Wan Q., Grewal R.K., et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006, 91:498-505.
16. Tuttle R.M., Leboeuf R. Investigational therapies for metastatic thyroid carcinoma. J Natl Compr Canc Netw 2007, 5:641-646.
17. Mazzaferri E.L., Kloos R.T. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001, 86:1447-1463.
18. Brierley J.D., Panzarella T., Tsang R.W., Gospodarowicz M.K., O'Sullivan B. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 1997, 79:2414-2423.
19. Verburg F.A., Mader U., Kruitwagen C.L., Luster M., Reiners C. A comparison of prognostic classification systems for differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2009, 26:26.
20. AJCC cancer staging manual 2002, Springer-Verlag, New York. 6th ed.
21. DeGroot L.J., Kaplan E.L., McCormick M., Straus F.H. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990, 71:414-424.
22. Pilli T., Brianzoni E., Capoccetti F., et al. A comparison of 1850 (50mCi) and 3700MBq (100mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007, 92:3542-3546.
23. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97:418-428.
24. Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006, 91:2892-2899.
25. Samaan N.A., Schultz P.N., Hickey R.C., et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992, 75:714-720.
26. Mazzaferri E.L., Jhiang S.M. Differentiated thyroid cancer long-term impact of initial therapy. Trans Am Clin Climatol Assoc 1994, 106:151-168. discussion 68-70.
27. Sawka A.M., Brierley J.D., Tsang R.W., et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 2008, 37:457-480. x.
28. Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998, 83:2638-2648. [see comments].
29. Hay I.D., Thompson G.B., Grant C.S., et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002, 26:879-885.
30. Sanders L.E., Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 1998, 133:419-425.
31. Kim S., Wei J.P., Braveman J.M., Brams D.M. Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg 2004, 139:390-394. discussion 3-4.
32. Sugitani I., Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocrinol J 1999, 46:209-216.
33. Lundgren C.I., Hall P., Dickman P.W., Zedenius J. Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer. Br J Surg 2007, 94:571-577.
34. Grewal R.K., Larson S.M., Pentlow C.E., et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med 2009, 50:1605-1610.
35. Walter M.A., Turtschi C.P., Schindler C., Minnig P., Muller-Brand J., Muller B. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med 2007, 48:1620-1625.
36. Rubino C., de Vathaire F., Dottorini M.E., et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003, 89:1638-1644.
37. Brown A.P., Chen J., Hitchcock Y.J., Szabo A., Shrieve D.C., Tward J.D. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008, 93:504-515.
38. Sawka A.M., Thabane L., Parlea L., et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009, 19:451-457.
39. Benua R.S., Cicale N.R., Sonenberg M., Rawson R.W. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962, 87:171-182.
40. Haynie T.P., Beierwaltes W.H. Hematologic changes observed following I-131 therapy for thyroid carcinoma. J Nucl Med 1963, 4:85-91.
41. Molinaro E., Leboeuf R., Shue B., et al. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. Thyroid 2009, 19:1035-1041.
42. Edmonds C.J., Hayes S., Kermode J.C., Thompson B.D. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 1977, 50:799-807.
43. Pacini F., Ladenson P.W., Schlumberger M., et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006, 91:926-932.
44. Chianelli M., Todino V., Graziano F.M., et al. Low-activity (2.0GBq; 54mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 2009, 160:431-436.
45. Tuttle R.M., Lopez N., Leboeuf R., et al. Radioactive iodine administered for thyroid remnant ablation following recombinant human TSH preparation also has an important adjuvant therapy function. Thyroid 2010, 20:1-7.
46. Tuttle R.M., Brokhin M., Omry G., et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008, 49:764-770.
47. Fatourechi V., Hay I.D., Mullan B.P., et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?. Thyroid 2000, 10:573-577.
48. Sherman S.I., Tielens E.T., Sostre S., Wharam M.D., Ladenson P.W. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994, 78:629-634.
49. Souza Rosario P.W., Barroso A.L., Rezende L.L., et al. Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution?. Clin Nucl Med 2004, 29:795-798.
50. Biondi B., Filetti S., Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005, 1:32-40.
51. McGriff N.J., Csako G., Gourgiotis L., Lori C.G., Pucino F., Sarlis N.J. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002, 34:554-564.
52. Biondi B., Cooper D.S. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010, 20:135-146.
53. Cooper D.S., Specker B., Ho M., et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998, 8:737-744.
54. Pujol P., Daures J.P., Nsakala N., Baldet L., Bringer J., Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996, 81:4318-4323.
55. Wang W., Larson S.M., Tuttle R.M., et al. Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001, 11:1169-1175.
56. Hyer S., Kong A., Pratt B., Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol) 2007, 19:83-86.
57. Kloos R.T., Duvuuri V., Jhiang S.M., Cahill K.V., Foster J.A., Burns J.A. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 2002, 87:5817-5820.
58. Vini L., Hyer S., Al-Saadi A., Pratt B., Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J 2002, 78:92-93.
59. Dottorini M.E., Lomuscio G., Mazzucchelli L., Vignati A., Colombo L. Assessment of female fertility and carcinogenesis after I-131 therapy for differentiated thyroid-carcinoma. J Nucl Med 1995, 36:21-27.
60. Sawka A.M., Lea J., Alshehri B., et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol 2008, 68:610-617.
61. Ceccarelli C., Bencivelli W., Morciano D., Pinchera A., Pacini F. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab 2001, 86:3512-3515.
62. Wichers M., Benz E., Palmedo H., Biersack H.J., Grunwald F., Klingmuller D. Testicular function after radioiodine therapy for thyroid carcinoma. Eur J Nucl Med 2000, 27:503-507.
63. Hyer S., Vini L., O'Connell M., Pratt B., Harmer C. Testicular dose and fertility in men following I-131 therapy for thyroid cancer. Clin Endocrinol 2002, 56:755-758.
64. Lushbaugh C.C., Casarett G.W. The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer 1976, 37:1111-1125.
65. Sarkar S.D., Beierwaltes W.H., Gill S.P., Cowley B.J. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 1976, 17:460-464.